Clinical trial: Extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 4, 2009, Pages 343-351

  Nagaki, M ^a   Shimizu, M ^b   Sugihara, J I ^b   Tomita, E ^c   Sano, C ^a   Naiki, T ^a   Kimura, K ^a   Amano, K ^d   Sakai, T ^d   Ninomiya, M ^e   Kojima, T ^f   Katsumura, N ^g   Fujimoto, M ^h   Moriwaki, H ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d Hashima City Hospital   (Japan)

^e Gihoku General Hospital   (Japan)

^f ASAHI UNIVERSITY   (Japan)

^g Chuno Hospital   (Japan)

^h Department of Internal Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS GENOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651156247     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04048.x     Document Type: Article

References (21)

1. Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: management of hepatitis C: 2002. Hepatology 2002 36 (Suppl S1 20.
2. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 65.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
4. Hadziyannis S, Sette H Jr., Morgan TR, et al. Peginterferon-alfa-2a plus ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 40 : 346 55.
5. Nagaki M, Imose M, Naiki T, et al. Prospective study on early virologic response to treatment with interferon alpha-2b plus rebavirin in patients with chronic hepatitis C genotype 1b. Hepatol Res 2005 33 : 285 91.
6. Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 52.
7. Ferenci P, Fried MW, Shifmann ML, et al. Predicting sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. J Hepatol 2005 43 : 425 33.
8. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006 44 : 97 103.
9. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 71.
10. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004 189 : 964 70.
11. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 130 : 1086 97.
12. Sánchez-Tapias JM, Diago M, Escartín P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 : 451 60.
13. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007 46 : 1688 94.
14. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008 47 : 43 50.
15. Kuboki M, Iino S, Okuno T, et al. Peginterferon α-2a (40KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroen Hepatol 2007 22 : 645 52.
16. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 1994 19 : 1513 20.
17. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Viol 1992 73 : 673 9.
18. Ohno T, Mizokami M, Wu R-R, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997 35 : 201 7.
19. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in NS5A region. J Clin Invest 1995 96 : 224 30.
20. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007 46 : 403 10.
21. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 9.